|
Healthy female volunteers, aged 18 years or older |
|
|
|
|
with mild to moderate acne |
|
|
|
|
Subjects must have between 10-100 non-inflammatory lesions and 10-50 inflammatory lesions but no more than 2 nodular lesions and no cysts on their face |
|
|
|
|
If applicable, users of estrogens/birth control pills must have been on the treatment regimen for at least 3 months and be willing to continue use for study duration |
|
|
|
|
Females of child-bearing potential (FCBP): A female is considered not to be of |
|
|
|
|
childbearing potential if she is post-menopausal with at least 12 consecutive |
|
|
|
|
months of amenorrhea or has undergone surgical sterilization. While on the |
|
|
|
|
study, FCBP who engage in activity in which conception is possible must use |
|
|
|
|
one of the approved contraceptive options described |
|
|
|
|
below |
|
|
|
|
Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR |
|
|
|
|
Option 2: Male or female condom (latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]; PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide |
|
|
|
|
Willing to follow study instructions and available to attend the study visits |
|
|
|
|
Willing to provide written informed consent and sign photography release |
|
|
|
|
Female subjects: Self-reported pregnant or breast feeding, or planning to become pregnant during the course of the study
|
|
|
|
|
Known allergy or hypersensitivity to acne treatment products
|
|
|
|
|
Current skin disease of any type in the test area (e.g. eczema, psoriasis, rosacea, seborrheic dermatitis, vitiligo, etc.), or under the treatment of a doctor for any skin condition
|
|
|
|
|
Have any cystic acne, acne conglobate, acne fulminans, or secondary acne (chloracne or drug-induced acne) in the test area
|
|
|
|
|
Any conditions on the test site that would interfere with evaluations (i.e. tattoos, scars, open cuts, sunburn, piercings, excessive hair, etc.)
|
|
|
|
|
Use of topical treatments such as OTC (over the counter) acne medication topical anti-inflammatory medications, salicylic acid, corticosteroids, antibiotics, anti-bacterials, peroxide-containing products, or retinoids within 2 weeks of baseline
|
|
|
|
|
Use of depigmenting medications such as hydroquinone during the 14 days prior to the study start; Insulin dependent diabetes
|
|
|
|
|
Concurrent medication that might affect the response to the test articles including routine use of anti-inflammatory medications, anti-histamines, and steroids
|
|
|
|
|
History of Crohn's disease, or clinically significant enteritis (regional enteritis, ulcerative colitis, pseudomembranous colitis, antibiotic-associated colitis)
|
|
|
|
|
Microdermabrasion or laser treatment in the test area within six months of the study
|
|
|
|
|
Medical condition which, in the opinion of the Investigator, would compromise the safety of the subject or confound study results
|
|
|
|
|
Use of systemic antibiotics, corticosteroids, antimalarials or oral dapsone within 4 weeks of baseline
|
|
|
|
|
Use of other anti-acne medications, including isotretinoin or spironolactone, within 6 months of baseline
|
|
|
|
|
Participation on an investigational drug study within 4 months of the baseline visit
|
|
|
|